
GZP2 is a clinical research study from Eli Lilly and Company. It is testing if an investigational medicine (a medicine being studied) can safely help people with obesity or overweight

GZP2 is a clinical research study from Eli Lilly and Company. It is testing if an investigational medicine (a medicine being studied) can safely help people with obesity or overweight

Consider joining a clinical study If you have high blood pressure, diabetes and cardiovascular disease, our clinical study could be a good fit for you. While lifestyle changes and current medicines offer some protection, many people with these conditions still experience disease progression that increases their risk of further cardiovascular complications and kidney damage.

The GN02 study is a new clinical research study from Eli Lilly and Company. GN02 is a weight management study. It will test if an investigational medicine can safely reduce body weight in people with type 2 diabetes and obesity or overweight when compared to placebo.
Investigational medicine means it is still being tested in clinical research studies. A placebo looks the same as an investigational medicine but does not have any real medicine in it.
Yes, you may be able to join the study if you:
BMI stands for body mass index. It is a number that compares a person’s weight to their height. It can be used to tell if a person may be at risk of some health conditions.
For more information: 786-772-0510

LAA2 is a new clinical research study from Eli Lilly and Company. It is testing if an investigational medicine (a medicine being studied) may help treat people with obesity or overweight and type 2 diabetes.

Your participation in the study will help to determine whether an investigational vaccine helps to provide protection against RSV in different populations.